HIV Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Mode, Product, End Use, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
HIV Diagnostics Market size was over USD 1.3 billion in 2026 and is likely to grow at a 4.75% CAGR between 2027 and 2036, reaching USD 2.07 billion by 2036. The industry revenue for 2027 is calculated at USD 1.35 billion.
Get more details on this report
Request Free Sample ReportHIV Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America led with a 29.05% share in 2026, supported by established screening programs, laboratory infrastructure, reimbursement pathways, and advanced diagnostic technology adoption.
- Asia Pacific is projected to grow at a 6.33% CAGR, driven by expanding healthcare access, stronger screening initiatives, and wider adoption of scalable diagnostic solutions.
Segment Momentum
- Lab-based testing held an 88.26% share in 2026 due to its role in confirmatory testing, established clinical workflows, and compatibility with high-volume testing, reporting, and procurement systems across formal healthcare settings.
- Software and Services are the fastest-growing product segment as testing programs increasingly require data management, workflow coordination, reporting integration, and operational support across expanding diagnostic networks.
Market Expansion Drivers
- Rising global HIV burden increasing demand for early detection and routine screening programs.
- Expansion of point-of-care and rapid diagnostic testing improving access in low-resource regions.
- Government-led awareness and testing initiatives driving widespread voluntary HIV screening adoption.
Leading Market Participants
- Major companies in the HIV diagnostics market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (United States), Beckman Coulter, Inc. (United States), bioMérieux SA (France), Sysmex Corporation (Japan), OraSure Technologies, Inc. (United States), Danaher Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.3 billion
- 2027 Estimated Market Size: USD 1.35 billion.
- Projected Market Size: USD 2.07 billion by 2036
- Growth Forecast: 4.75% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Lab-based (Mode) | Consumables (Product) | Diagnostic Laboratories (End Use) | Antibody Test (Test Type)
- Emerging Opportunity Segment: Self-test (Mode) | Software and Services (Product) | Home Settings (End Use) | Antibody Test (Test Type)
Market Growth Drivers and Industry Trends
Rising global HIV burden increasing demand for early detection and routine screening programs
A persistent global HIV burden is supporting the HIV diagnostics market growth by increasing the need for accessible testing that can identify infections at an earlier stage. Routine screening enables individuals to determine their status even when symptoms are absent, while early diagnosis allows healthcare providers to connect patients with appropriate clinical management and monitoring. Expanding testing coverage across different population groups also strengthens the role of diagnostic services within broader HIV prevention and care strategies.
Expansion of point-of-care and rapid diagnostic testing improving access in low-resource regions
The HIV diagnostics market is benefiting from wider deployment of point-of-care and rapid testing technologies, particularly in settings where centralized laboratory infrastructure may be limited. These approaches can reduce dependence on complex laboratory workflows and enable testing to be performed closer to communities and healthcare facilities. Faster access to results can improve linkage to follow-up care while supporting screening activities in geographically dispersed and resource-constrained populations.
Government-led awareness and testing initiatives driving widespread voluntary HIV screening adoption
Government-supported awareness campaigns and testing programs are contributing to the HIV diagnostics market growth by encouraging individuals to participate in voluntary screening and increasing public understanding of the importance of knowing HIV status. Organized initiatives can improve awareness of available testing services, reduce barriers associated with seeking diagnostic support, and integrate screening into broader public health activities. Greater outreach through community and healthcare channels can also encourage more regular testing among populations with differing levels of access to formal healthcare services.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global HIV burden increasing demand for early detection and routine screening programs | 2.00% | High | Africa, North America, Asia Pacific | High | Near Term |
| Expansion of point-of-care and rapid diagnostic testing improving access in low-resource regions | 1.80% | High | Africa, Asia Pacific, Latin America | High | Mid Term |
| Government-led awareness and testing initiatives driving widespread voluntary HIV screening adoption | 1.50% | High | North America, Europe, Asia Pacific | High | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
Holding a 29.05% share of the HIV diagnostics market in 2026, North America maintained the largest regional position due to its well-developed healthcare infrastructure and broad availability of advanced diagnostic technologies. Strong emphasis on early detection, routine screening, and disease monitoring supports consistent demand for diagnostic testing. The region also benefits from established laboratory networks, high awareness of preventive healthcare, and continued integration of innovative testing methods across clinical and community healthcare settings.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by increasing awareness of HIV testing, expanding healthcare access, and growing efforts to strengthen disease surveillance and early diagnosis. Improvements in diagnostic infrastructure and wider availability of rapid and laboratory-based testing are helping broaden access across urban and underserved populations. Rising healthcare investment and the growing focus on preventive care are also creating favorable conditions for the adoption of HIV diagnostic solutions.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
High-Accuracy DiagnosticsGermany prioritizes HIV diagnostics with strong analytical performance and compatibility with modern laboratory systems. Healthcare providers emphasize standardized testing protocols and reliable assay quality to support consistent clinical decision-making.
France 🇫🇷
Preventive Testing ProgramsFrance emphasizes HIV diagnostics that complement preventive healthcare initiatives and routine screening services. Diagnostic suppliers support healthcare providers with accurate testing solutions designed for efficient integration into public and clinical health programs.
Italy 🇮🇹
Accessible Clinical DiagnosticsItaly's HIV diagnostics market prioritizes dependable testing technologies that improve accessibility across hospitals and diagnostic laboratories. Healthcare institutions increasingly adopt streamlined diagnostic workflows that support earlier confirmation and effective patient care coordination.
Japan 🇯🇵
Routine Screening IntegrationJapan emphasizes HIV diagnostics that support routine screening through reliable laboratory platforms and efficient clinical workflows. Diagnostic manufacturers continue refining assay performance while improving usability across hospitals and specialized healthcare facilities.
South Korea 🇰🇷
Rapid Testing ExpansionSouth Korea advances HIV diagnostics through broader availability of rapid testing technologies alongside centralized laboratory services. Healthcare organizations focus on efficient diagnosis and accessible testing pathways that enhance overall clinical responsiveness.
United States 🇺🇸
Comprehensive Testing AccessThe U.S. HIV diagnostics market focuses on expanding access to laboratory-based and point-of-care testing across diverse healthcare settings. Diagnostic providers emphasize rapid result delivery, workflow integration, and technologies that support routine screening and ongoing patient management.
Segment Leadership and Growth Trends
HIV Diagnostics Market Share (%), by Mode, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportMode Segment Analysis: Lab-based (Largest Segment) vs Self-test (Fastest-Growing Segment)
Lab-based testing dominated the HIV diagnostics market in 2026, accounting for 88.26% of the market. Its leading position reflects the established role of laboratory testing in providing reliable HIV diagnosis through controlled testing environments, trained professionals, and established quality-assurance procedures. Laboratory-based diagnostics are particularly important where confirmatory testing, clinical evaluation, and integration with broader healthcare services are required. Continued demand for accurate diagnosis and structured testing pathways supports the strong presence of laboratory-based approaches.
Self-test is emerging as the fastest-growing testing mode as individuals increasingly seek convenient, private, and accessible approaches to HIV screening. Self-testing can reduce barriers associated with visiting healthcare facilities and may support earlier awareness among populations that face challenges accessing conventional diagnostic services. Greater emphasis on decentralized testing, patient autonomy, privacy, and expanded HIV screening access is encouraging wider adoption of self-test solutions.
Product Segment Analysis: Consumables (Largest Segment) vs Software and Services (Fastest-Growing Segment)
The consumables segment held the largest share of the HIV diagnostics market in 2026 at 52.47%, reflecting the recurring requirement for diagnostic reagents, test components, collection materials, and other supplies used during HIV testing. Continuous diagnostic activity creates ongoing demand for consumable products, while their direct role in testing workflows makes them essential to laboratory and decentralized diagnostic operations. Expansion of HIV screening and monitoring activities continues to sustain consumption, reinforcing the segment's established market position.
Software and services are experiencing the fastest growth as HIV diagnostics increasingly incorporate digital workflow management, data analysis, connectivity, and service-based support. Healthcare providers and laboratories are placing greater emphasis on efficient test administration, result management, reporting, and integration with broader healthcare information systems. Increasing digitalization of diagnostic operations is therefore creating opportunities for software-enabled platforms and specialized services that improve workflow efficiency and support more connected HIV testing environments.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Mode | Self-test, Lab-based | Lab-based | Self-test |
| Product | Consumables, Instruments, Software and Services | Consumables | Software and Services |
| End Use | Diagnostic Laboratories, Hospitals & Clinics, Home Settings | Diagnostic Laboratories | Home Settings |
| Test Type | Antibody Test, Viral Load Test, CD4 Test, Others | Antibody Test | Antibody Test |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the HIV diagnostics market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. QIAGEN N.V. (Netherlands)
5. Becton Dickinson and Company (United States)
6. Beckman Coulter Inc. (United States)
7. bioMérieux SA (France)
8. Sysmex Corporation (Japan)
9. OraSure Technologies Inc. (United States)
10. Danaher Corporation (United States)
The HIV diagnostics market is being shaped by rising demand for rapid, accessible, and highly sensitive testing solutions. Companies are investing in next-generation diagnostic platforms that improve detection accuracy and reduce turnaround times across healthcare settings. Expansion of portable and decentralized testing technologies is also supporting broader market growth.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Beckman Coulter Inc. (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Sysmex Corporation (Japan) | |||||||
| OraSure Technologies Inc. (United States) | |||||||
| Danaher Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Lord’s Mark | May-26 | Lord’s Mark secured inclusion into a select group of nine globally recognized organizations in the HIV self-testing segment. This recognition elevates the company's competitive standing within the expanding international market for accessible, consumer-facing HIV diagnostic kits. |
| bioMérieux | Jun-25 | bioMérieux signed a definitive agreement to acquire the core assets of US-based Day Zero Diagnostics, including its proprietary next-generation sequencing workflows, reagents, and bioinformatics software. This acquisition enhances bioMérieux's precision diagnostics portfolio and accelerates its capabilities in rapid testing innovation. |
| OraSure Technologies | Jan-25 | OraSure Technologies secured US FDA approval for a labeling update to its OraQuick HIV Self-Test, lowering the authorized user age from 17 to 14 years old. This regulatory expansion broadens the product's addressable adolescent market segment and enhances early-detection testing access. |
| MedMira | Jan-25 | MedMira received regulatory approval from Health Canada for its RevealRapid G4 Test, a rapid point-of-care HIV-1/2 antibody diagnostic that delivers results within seconds. The approval introduces high-velocity testing efficiencies into Canadian clinical and point-of-care settings. |
| Abbott | Dec-24 | Abbott established a strategic healthcare access partnership in Nigeria alongside Siemens Healthineers AG, Abbott Laboratories GmbH, and local partner Tanit Medical Engineering. The collaborative agreement focuses on strengthening domestic healthcare infrastructure and improving regional deployment of diagnostic services. |
| Cepheid | Apr-24 | Cepheid obtained World Health Organization prequalification for its Xpert HIV-1 Qual XC point-of-care diagnostic test. The certification validates the test's performance standards for early infant HIV detection and broadens international procurement opportunities using dried blood spots. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
HIV Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Plasma, Serum, Oral Fluid, Other Specimens |
| Testing Purpose | Screening & Diagnosis, Treatment Monitoring, Early Infant Diagnosis, Prevention & Surveillance |
| Procurement Model | Public Health Programs, Hospital & Laboratory Procurement, Private Healthcare Procurement, International Aid & Donor-funded Procurement |
HIV Diagnostics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| National HIV Screening Program Opportunity Assessment |
|
| Donor Funding and Procurement Intelligence |
|
| Point-of-Care Testing Adoption Outlook |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of HIV diagnostics?
What are the growth projections for the HIV diagnostics industry?
How are routine screening programs influencing demand in the HIV diagnostics market?
Why are point-of-care HIV diagnostics becoming a strategic investment priority?
Why does lab-based testing dominate the HIV diagnostics market?
Which product segment is growing fastest in the HIV diagnostics market?
Why does North America lead the HIV diagnostics market?
How is Asia Pacific driving future growth in HIV diagnostics?
Which companies dominate the HIV diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization